Nurami Medical

Executive Summary

Nurami Medical is an Israeli medtech company pioneering nanofiber-based biomaterial implants for soft tissue repair, with a primary focus on neurosurgical dura closure. Its proprietary electrospinning platform produces ArtiFascia®, an ultra-thin, pliable, and watertight graft that supports native tissue regeneration while minimizing cerebrospinal fluid leaks. ArtiFascia is FDA-cleared and commercially available in the United States, addressing a critical need in cranial and spinal surgeries where dural repair is essential to prevent complications. The company leverages its advanced manufacturing to deliver consistent, high-quality implants that outperform traditional synthetic and biologic grafts in handling and leak prevention. The global dural repair market is valued at over $1.5 billion and growing, driven by rising neurosurgical procedures and demand for safer closure solutions. Nurami’s differentiated technology positions it to capture share from established players by offering a cost-effective, ready-to-use implant with superior handling characteristics. Beyond the initial neurosurgical indication, the company is exploring expansion into other soft tissue repairs, such as hernia and tendon repair, which could multiply its addressable market. With a strong IP portfolio, manufacturing expertise, and a clear regulatory pathway, Nurami Medical is well-positioned to scale commercialization and pursue strategic partnerships to broaden its product line and geographic reach.

Upcoming Catalysts (preview)

• Q2 2026Expansion into spinal dural repair indication70% success
• Q4 2026CE mark approval for European market entry60% success
• Q3 2026Publication of pivotal clinical trial results in neurosurgery journal75% success